The U.S. House Oversight and Reform Committee issued a blistering report late last week accusing brand pharmaceutical manufacturers of systematically jacking up prices on their drugs in the United States.
Pharmaceutical Research and Manufacturers of America (PhRMA) called it a
…SPONSORED CONTENT
The word “innovation” gets tossed around so much these days that we almost forget its meaning—the introduction of new and different ideas for out-of-the-box problem solving that have meaningful impacts. Yet, innovation is different in every industry, and it’s essential in a field as complex as 340B.
To get a handle on it, we sat down with healthcare technology veteran Andrew Stevenson, VP of Product Strategy and Business Development, and 340B industry expert Christy Bryant, VP, Customer Service & Regulatory Affairs at Macro Helix, a third-party administrator that facilitates the 340B programs of more than 900 covered entities as well as hospital-owned and retail pharmacies. Responsible for supporting customer relationships, and driving the execution of critical innovation programs with Macro Helix’s customers, they have valuable insights to share for a 340B community faced with new challenges almost daily.
In a nutshell, what is Macro Helix? How do you help customers succeed with 340B?
Christy Bryant: We help healthcare entities maximize their 340B
…
As California’s Medicaid program moves toward implementing a fee-for-service payment structure for drug coverage, one of the primary foes of the transition has returned to court to obtain a temporary restraining order.
The new Medi-Cal Rx program is intended to
…
The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.
The committee released the
A federal district judge in Washington, D.C., has paused Boehringer Ingelheim’s (BI) 340B contract pharmacy lawsuit while the federal government decides whether to appeal the same judge’s Nov. 5 joint ruling in Novartis and United Therapeutics’ (UT) contract pharmacy suits.
…
Drug manufacturer Lilly said this morning it looks forward to reviewing the Biden administration’s proposed new 340B administrative dispute resolution (ADR) regulation when it becomes available “and hope[s] that it addresses the serious shortcomings of the current rule.”
“As Lilly
…SPONSORED CONTENT
This strategy could save the 340B proceeds at your organization
Today, underinsured or uninsured patients who are undergoing treatment with a Gilead HIV treatment or preventative medication may be eligible to receive those medications at no cost through Gilead’s Advancing Access program. Under this program, covered entities are able to receive full 340B proceeds from these dispenses and can use these funds to support and expand critical community programs and outreach efforts.
As most Ryan White and STI grantee covered entities probably are aware, on January 1, 2022, Gilead will no longer reimburse pharmacies at full retail price under its Advancing Access program. This will eliminate nearly all the 340B proceeds you may be currently receiving under this program and could have a huge impact on your business and the
…
The Biden administration plans to replace its 340B administrative dispute resolution (ADR) regulation with an entirely new rule that “better aligns with the president’s priorities on drug pricing [and] better reflects the current state of the 340B program.”
The administration
…
The ban on 340B pricing on orphan drugs for over 1,000 hospitals may give companies that make drugs used primarily for common diseases or conditions a strong financial incentive to get an orphan designation for those drugs, a federal watchdog
…*Sign up for news summaries and alerts from 340B Report
